Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1966 1
1969 1
1970 1
1972 1
1973 3
1974 3
1975 2
1976 1
1977 1
1978 1
1979 3
1980 3
1981 3
1982 3
1983 1
1985 2
1986 2
1987 1
1988 1
1990 1
2018 1
2019 2
2020 2
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.
Rovers KP, Bakkers C, Nienhuijs SW, Burger JWA, Creemers GM, Thijs AMJ, Brandt-Kerkhof ARM, Madsen EVE, van Meerten E, Tuynman JB, Kusters M, Versteeg KS, Aalbers AGJ, Kok NFM, Buffart TE, Wiezer MJ, Boerma D, Los M, de Reuver PR, Bremers AJA, Verheul HMW, Kruijff S, de Groot DJA, Witkamp AJ, van Grevenstein WMU, Koopman M, Nederend J, Lahaye MJ, Kranenburg O, Fijneman RJA, van 't Erve I, Snaebjornsson P, Hemmer PHJ, Dijkgraaf MGW, Punt CJA, Tanis PJ, de Hingh IHJT; Dutch Peritoneal Oncology Group and the Dutch Colorectal Cancer Group. Rovers KP, et al. JAMA Surg. 2021 Aug 1;156(8):710-720. doi: 10.1001/jamasurg.2021.1642. JAMA Surg. 2021. PMID: 34009291 Free PMC article. Clinical Trial.
Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer.
Claessens AKM, Busschbach JJV, Ramaekers BLT, Erdkamp FLG, Bouma JM, van Leeuwen-Stok AE, Tjan-Heijnen VCG, Bos MEMM; Dutch Breast Cancer Research Group (BOOG). Claessens AKM, et al. Among authors: bouma jm. Acta Oncol. 2022 May;61(5):619-624. doi: 10.1080/0284186X.2022.2033832. Epub 2022 Feb 9. Acta Oncol. 2022. PMID: 35139727 No abstract available.
Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer.
Claessens AKM, Erdkamp FLG, Lopez-Yurda M, Bouma JM, Rademaker-Lakhai JM, Honkoop AH, de Graaf H, Tjan-Heijnen VCG, Bos MEMM; Dutch Breast Cancer Research Group (BOOG). Claessens AKM, et al. Among authors: bouma jm. Acta Oncol. 2020 Jun;59(6):713-722. doi: 10.1080/0284186X.2020.1731923. Epub 2020 Mar 6. Acta Oncol. 2020. PMID: 32141389 Clinical Trial.
Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG).
Claessens AKM, Bos MEMM, Lopez-Yurda M, Bouma JM, Rademaker-Lakhai JM, Honkoop AH, de Graaf H, van Druten E, van Warmerdam LJC, van der Sangen MJC, Tjan-Heijnen VCG, Erdkamp FLG; Dutch Breast Cancer Research Group (BOOG). Claessens AKM, et al. Among authors: bouma jm. Breast Cancer Res Treat. 2018 Nov;172(2):413-423. doi: 10.1007/s10549-018-4906-8. Epub 2018 Aug 18. Breast Cancer Res Treat. 2018. PMID: 30121808 Clinical Trial.
The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancer.
Claessens AKM, Timman R, Busschbach JJ, Bouma JM, Rademaker-Lakhai JM, Erdkamp FLG, Tjan-Heijnen VCG, Bos MEMM; Dutch Breast Cancer Research Group (BOOG). Claessens AKM, et al. Among authors: bouma jm. Breast Cancer Res Treat. 2020 Feb;179(3):677-685. doi: 10.1007/s10549-019-05495-3. Epub 2019 Nov 28. Breast Cancer Res Treat. 2020. PMID: 31782032 Free PMC article.
Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6).
Rovers KP, Bakkers C, Simkens GAAM, Burger JWA, Nienhuijs SW, Creemers GM, Thijs AMJ, Brandt-Kerkhof ARM, Madsen EVE, Ayez N, de Boer NL, van Meerten E, Tuynman JB, Kusters M, Sluiter NR, Verheul HMW, van der Vliet HJ, Wiezer MJ, Boerma D, Wassenaar ECE, Los M, Hunting CB, Aalbers AGJ, Kok NFM, Kuhlmann KFD, Boot H, Chalabi M, Kruijff S, Been LB, van Ginkel RJ, de Groot DJA, Fehrmann RSN, de Wilt JHW, Bremers AJA, de Reuver PR, Radema SA, Herbschleb KH, van Grevenstein WMU, Witkamp AJ, Koopman M, Haj Mohammad N, van Duyn EB, Mastboom WJB, Mekenkamp LJM, Nederend J, Lahaye MJ, Snaebjornsson P, Verhoef C, van Laarhoven HWM, Zwinderman AH, Bouma JM, Kranenburg O, van 't Erve I, Fijneman RJA, Dijkgraaf MGW, Hemmer PHJ, Punt CJA, Tanis PJ, de Hingh IHJT; Dutch Peritoneal Oncology Group (DPOG); Dutch Colorectal Cancer Group (DCCG). Rovers KP, et al. Among authors: bouma jm. BMC Cancer. 2019 Apr 25;19(1):390. doi: 10.1186/s12885-019-5545-0. BMC Cancer. 2019. PMID: 31023318 Free PMC article. Clinical Trial.
Facilitation of lysosome disruption by ATP at low pH.
Huisman W, Bouma JM, Gruber M. Huisman W, et al. Among authors: bouma jm. Nature. 1974 Aug 2;250(465):428-9. doi: 10.1038/250428a0. Nature. 1974. PMID: 4851997 No abstract available.
42 results